The coronavirus crisis has been a carousel of historic events, featuring pervasively high volatility in stock markets and in the medical and economic situations. Sometimes it is difficult to see the forest for the trees, affecting economic decision-making. The successful efficacy results of the Pfizer and Moderna vaccines trials has been one of the recent, wave-making headlines. The news reinforces our conviction in the predictions we made back in May, against widespread scepticism, that there would be one to three vaccines approved by late 2021.